History of DiaSys Diagnostics Systems GmbH
1991
DiaSys founded by Dr. Günther Gorka, Rolf Greiner and Dr. Manfred Probst.
1991
Worldwide first liquid stable reagents to determine of enzymes and substrates in clinical chemistry.
1993
DiaSys relocates to a proprietary building in Holzheim.
1993
Launch of first turbidimetric tests.
1994
Export activities start in 17 countries.
1997
Introduction of CRP FS for inflammation testing.
1998
TruLab line of quality control products.
1999
Extensive expansion of reagent production capacity thanks to construction of a new building. Foundation of DiaSys France, the company's first subsidiary.
2000
First joint venture in China. 1st international distributor meeting.
2000
DiaSys enters instrument business with StarDust MC15 semi-automated analyzer.
2001
First step into point-of-care testing with SensoStar glucose and lactate testing device.
2003
Takeover of the clinical chemistry product activities of Merck KGaA, Darmstadt.
2003
CRP U-hs - innovative reagent for universal and high sensitive testing.
2004
Launch of reagents for food analysis.
2005
Acquisition of shares in Rolf Greiner Biochemica GmbH.
2005
Diabetes monitoring made easy with DiaSys oneHbA1c FS.
2006
15 year anniversary
2006
Foundation of DiaSys Russia and DiaSys Japan. Establishment of DiaSys Technologies for system development.
2007
Acquisition of Poles France enhances the instrument platform for DiaSys reagents. pes diagnosesysteme in Leipzig joins DiaSys group.
2008
New building at DiaSys headquarters.
2008
Introduction of respons®920 fully automated analyzer for small and medium labs.
2009
Acquisition of shares in Kovalent Ltd. in Brazil. Inauguration of DiaSys Diagnostic Products in Shanghai.
2009
InnovaStar® - POC testing in lab quality.
2010
Cooperation with JEOL Ltd. of Tokyo. Market launch BioMajesty® JCA-BM6010/C for higher throughputs - most compact and efficient.
2010
In 2010 the second member of the respons® family was launched.
2011
Celebrating 20 years DiaSys products with international distributor meeting.
2012
Alliance with Proline setting up reagent production in Indonesia.
2013
International Distributor Meeting in Dubai.
2014
Joint venture with Leadman of Bejing, Rep. of China.
DiaSys acquires diagnostic division of Piramal, India reestablishing DiaSys India with sales, marketing, R&D, production and international business center for POCT QDx® brand.
2014
DiaSys establishes subsidiary in U.S.A. Launch of respons®910VET for highest performance in veterinary diagnostics.
2015
New QDx® point-of-care product line gives immediate results for prompt therapeutic decisions.
2016
Participation in DiaServe laboratories. 25 years Choosing Quality.
2019
DiaSys introduces a new enzymatic HbA1c assay - HbA1c net FS - for diagnosis and monitoring of diabetes.
2019
DiaSys expands the respons®system family by respons®940, a clinical chemistry random access analyzer with a throughput of 640 tests/h including ISE measurements.
2020
Introduction of an immunoturbidimetric procalcitonin assay - Procalcitonin FS - for sepsis diagnosis.
2021
DiaSys celebrates 30 years of ‘Choosing Quality’.
2021
Introduction of a COVID-19 panel consisting of rapid tests and the immunoturbidimetric assay, SARS-CoV-2 UTAB FS, for the determination of SARS-CoV-2 total antibodies.
2021
Foundation of a strategic partnership with ROBERT RIELE GmbH & Co KG, Berlin, for the exclusive marketing of the Photometer 505.
2022
Audited in November 2021, DiaSys obtained confirmation of compliance regarding requirement of Medical Device Single Audit Approach.
2023
By the end of 2023, DiaSys Diagnostic Systems GmbH have entered into an agreement with the Dutch subsidiary of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. by which Mindray has acquired 75% stake in DiaSys group.
2024
Launch of one step HbA1c analyzer respons®A1c
